PFE Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of -19.69%. Pfizer Inc.'s return on equity of 10.84% beat Moderna, Inc.'s return on equity of -30.18%.

Pfizer Inc. has a consensus price target of $29.04, signalling upside risk potential of 13%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Pfizer Inc., analysts believe Moderna, Inc. is more attractive than Pfizer Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.69%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Moderna, Inc. quarterly revenues of $1B. Pfizer Inc.'s net income of $3.6B is higher than Moderna, Inc.'s net income of -$200M. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.98x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.34x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of 38.89%. Pfizer Inc.'s return on equity of 10.84% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Pfizer Inc. has a consensus price target of $29.04, signalling upside risk potential of 13%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.07%. Given that Pfizer Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.69%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Pfizer Inc.'s net income of $3.6B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.98x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.34x versus 5.59x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of --. Pfizer Inc.'s return on equity of 10.84% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Pfizer Inc. has a consensus price target of $29.04, signalling upside risk potential of 13%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 142.13%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.69%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Pfizer Inc.'s net income of $3.6B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.98x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.34x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 21.32% compared to Pfizer Inc.'s net margin of 34.76%. Pfizer Inc.'s return on equity of 10.84% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Pfizer Inc. has a consensus price target of $29.04, signalling upside risk potential of 13%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Pfizer Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Pfizer Inc. has a beta of 0.457, which suggesting that the stock is 54.271% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Pfizer Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 6.69%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer Inc. pays 119.94% of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pfizer Inc. quarterly revenues are $16.7B, which are larger than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Pfizer Inc.'s net income of $3.6B is higher than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Pfizer Inc.'s price-to-earnings ratio is 14.98x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer Inc. is 2.34x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.